1-5 of 5
Kurt G. Pike
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically

Free
Lucy C. Riches, Antonio G. Trinidad, Gareth Hughes, Gemma N. Jones, Adina M. Hughes, Andrew G. Thomason, Paul Gavine, Andy Cui, Stephanie Ling, Jonathan Stott, Roger Clark, Samantha Peel, Pendeep Gill, Louise M. Goodwin, Aaron Smith, Kurt G. Pike, Bernard Barlaam, Martin Pass, Mark J. O'Connor, Graeme Smith, Elaine B. Cadogan
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2020) 19 (1): 13–25.
https://doi.org/10.1158/1535-7163.MCT-18-1394
Published: 03 January 2020
View article titled, Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically
Open the PDF for Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically in another window
Includes: Supplementary data
Journal Articles

Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice

Free
Jeremy Karlin, Jasmine Allen, Syed F. Ahmad, Gareth Hughes, Victoria Sheridan, Rajesh Odedra, Paul Farrington, Elaine B. Cadogan, Lucy C. Riches, Antonio Garcia-Trinidad, Andrew G. Thomason, Bhavika Patel, Jennifer Vincent, Alan Lau, Kurt G. Pike, Thomas A. Hunt, Amrita Sule, Nicholas C.K. Valerie, Laura Biddlestone-Thorpe, Jenna Kahn, Jason M. Beckta, Nitai Mukhopadhyay, Bernard Barlaam, Sebastien L. Degorce, Jason Kettle, Nicola Colclough, Joanne Wilson, Aaron Smith, Ian P. Barrett, Li Zheng, Tianwei Zhang, Yingchun Wang, Kan Chen, Martin Pass, Stephen T. Durant, Kristoffer Valerie
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (8): 1637–1647.
https://doi.org/10.1158/1535-7163.MCT-17-0975
Published: 31 July 2018
View article titled, Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice
Open the PDF for Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice in another window
Includes: Multimedia, Supplementary data
Journal Articles

Abstract A104: AZD1390, a potent and selective orally bioavailable blood-brain barrier-penetrant ATM inhibitor, radiosensitizes and improves survival of orthotopic glioma and metastatic brain tumor models

Free
Steve T. Durant, Kurt G. Pike, Nicola Colclough, Lucy Riches, Antonio Garcia-Trinidad, Thomas Hunt, Stephanie Ling, Jonathan Stott, Ian Barrett, Li Zheng, Yingchun Wang, Kan Chen, Tianwei Zhang, Venkatesh Pilla Reddy, Andrew Sykes, Peter Johnstrom, Gemma Jones, Andrew Pierce, Jeremy Karlin, Jenna Kahn, Jasmine Allen, Kristoffer Valerie, Ruth Illingworth, Martin Pass
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A104.
https://doi.org/10.1158/1535-7163.TARG-17-A104
Published: 01 January 2018
View article titled, Abstract A104: AZD1390, a potent and selective orally bioavailable blood-brain barrier-penetrant ATM inhibitor, radiosensitizes and improves survival of orthotopic glioma and metastatic brain tumor models
Journal Articles

Abstract A124: Discovery of the clinical candidate AZD1390: a high-quality, potent, and selective inhibitor of ATM kinase with the ability to cross the blood-brain barrier

Free
Kurt G. Pike
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A124.
https://doi.org/10.1158/1535-7163.TARG-17-A124
Published: 01 January 2018
View article titled, Abstract A124: Discovery of the clinical candidate AZD1390: a high-quality, potent, and selective inhibitor of ATM kinase with the ability to cross the blood-brain barrier
Journal Articles

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

Free
Sylvie M. Guichard, Jon Curwen, Teeru Bihani, Celina M. D'Cruz, James W.T. Yates, Michael Grondine, Zoe Howard, Barry R. Davies, Graham Bigley, Teresa Klinowska, Kurt G. Pike, Martin Pass, Christine M. Chresta, Urszula M. Polanska, Robert McEwen, Oona Delpuech, Stephen Green, Sabina C. Cosulich
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2015) 14 (11): 2508–2518.
https://doi.org/10.1158/1535-7163.MCT-15-0365
Published: 03 November 2015
View article titled, AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules
Open the PDF for AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules in another window
Includes: Supplementary data